For the quarter ending 2026-03-31, ENZN made $86,537K in revenue. -$6,689K in net income. Net profit margin of -7.73%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net sales | 86,537 | - | - | - |
| Cost of sales | 77,537 | - | - | - |
| Gross margin | 9,000 | - | - | - |
| Selling, general and administrative | 12,434 | - | - | - |
| General and administrative | - | 541* | 229 | 314 |
| Transaction expenses | - | 514* | 1,075 | 1,219 |
| Amortization of intangibles | 536 | - | - | - |
| Total operating expenses | - | 1,055 | 1,304 | 1,533 |
| Restructuring expense | 363 | - | - | - |
| Operating loss | -4,333 | -1,055* | -1,304 | -1,533 |
| Interest expense, net | -2,824 | - | - | - |
| Interest and dividend income | - | 426* | 496 | 501 |
| Other expense (income), net | 1,183 | - | - | - |
| Loss before income taxes | -5,974 | -630* | -808 | -1,032 |
| Income tax provision (benefit) | 748 | 58* | 16 | -42 |
| Net loss | -6,722 | - | - | - |
| Less net (loss) attributable to noncontrolling interests | -33 | - | - | - |
| Net (loss) income attributable to viskase companies, inc | -6,689 | -688* | -824 | -990 |
| Dividends on series c preferred stock | - | 531* | 531 | 531 |
| Net loss available to common shareholders | - | -1,219 | -1,355 | -1,521 |
| Basic EPS | -0.84 | -0.016 | -0.02 | -0.02 |
| Diluted EPS | -0.84 | -0.016 | -0.02 | -0.02 |
| Basic Average Shares | 7,931,249 | 74,215,000 | 74,215,000 | 74,215,000 |
| Diluted Average Shares | 7,931,249 | 74,215,000 | 74,215,000 | 74,215,000 |
ENZON PHARMACEUTICALS, INC. (ENZN)
ENZON PHARMACEUTICALS, INC. (ENZN)